| 史文俊,李 芳,安黎云.非小细胞肺癌患者血清Hsa_circ_0007142表达及其临床价值[J].肿瘤学杂志,2025,31(5):385-389. |
| 非小细胞肺癌患者血清Hsa_circ_0007142表达及其临床价值 |
| Expression of Serum Hsa_circ_0007142 in Patients with Non-Small Cell Lung Cancer and Its Clinicopathological Significance |
| 投稿时间：2025-01-19 |
| DOI：10.11735/j.issn.1671-170X.2025.05.B003 |
|
 |
| 中文关键词: 非小细胞肺癌 Hsa_circ_0007142 鳞状细胞癌抗原 细胞角蛋白19片段抗原21-1 诊断 |
| 英文关键词:non-small cell lung cancer Hsa_circ_0007142 squamous cell carcinoma antigen cytokeratin 19 fragment antigen 21-1 diagnosis |
| 基金项目:河北省医学科学研究课题（20251034） |
|
| 摘要点击次数: 13 |
| 全文下载次数: 5 |
| 中文摘要: |
| 摘 要：［目的］ 探讨非小细胞肺癌（non-small cell lung cancer，NSCLC）患者血清Hsa_circ_0007142表达及临床意义。［方法］ 选取2022年1月至2024年12月NSCLC患者91例（NSCLC组）、肺部良性疾病患者60例（良性组）和50名体检正常者（对照组）作为研究对象。91例NSCLC患者Ⅰ～ⅡA期34例和ⅡB～Ⅳ期57例。比较各组血清Hsa_circ_0007142、鳞状细胞癌抗原（squamous cell carcinoma antigen，SCCA）及细胞角蛋白19片段抗原21-1（cytokeratin 19 fragment antigen 21-1，CYFRA21-1）水平，分析其与NSCLC临床病理特征的关系。血清Hsa_circ_0007142、SCCA及CYFRA21-1水平对Ⅰ～ⅡA期NSCLC的诊断价值应用受试者工作特征（receiver operating characteristic，ROC）曲线评估。［结果］ NSCLC组血清Hsa_circ_0007142（4.36±1.50 vs 1.08±0.36，0.90±0.27）、 SCCA［（4.83±1.62） ng/mL vs （0.92±0.31） ng/mL，（0.75±0.14） ng/mL］及CYFRA21-1［（6.84±2.10）ng/mL vs （2.50±0.58） ng/mL，（1.81±0.35） ng/mL］ 水平均明显高于良性组和对照组（P均<0.001）。ⅡB～Ⅳ期NSCLC患者血清Hsa_circ_0007142（5.75±1.96 vs 3.10±1.05）、SCCA［（6.05±2.04） ng/mL vs （3.64±1.21） ng/mL］及CYFRA21-1［（8.70±2.73） ng/mL vs （5.06±1.70） ng/mL］水平均明显高于Ⅰ～ⅡA期组（P均<0.001）。血清Hsa_circ_0007142表达水平在低分化、淋巴结转移、远处转移、SCCA阳性以及CYFRA21-1阳性的NSCLC中明显升高（P均<0.05）。ROC曲线分析显示，Hsa_circ_0007142≥2.85诊断Ⅰ～ⅡA期NSCLC的特异度最高（87.4%），Hsa_circ_0007142联合SCCA及CYFRA21-1诊断Ⅰ～ⅡA期NSCLC的曲线下面积最大（0.938，95%CI：0.877～0.995），灵敏度最高（97.5%）。［结论］ 血清Hsa_circ_0007142水平在NSCLC患者中明显升高，其升高与临床病理特征进展有关。Hsa_circ_0007142、SCCA及CYFRA21-1联合检测对Ⅰ～ⅡA期NSCLC诊断具有一定价值。 |
| 英文摘要: |
| Abstract：［Objective］ To investigate the expression and clinicopathological significance of serum Hsa_circ_0007142 in patients with non-small cell lung cancer (NSCLC). ［Methods］ Ninety one NSCLC patients (NSCLC group)， 60 benign lung disease patients (benign group)， and 50 healthy subjects (control group) were enrolled from January 2022 to December 2024. In NSCLC patients， there were 34 cases of stage Ⅰ~ⅡA and 57 cases of stage ⅡB~Ⅳ. The serum Hsa_circ_0007142， squamous cell carcinoma antigen (SCCA) and cytokera-tin 19 fragment antigen21-1 (CYFRA21-1) were measured and compared among groups， and their relationship with the clinicopathological characteristics of NSCLC was analyzed. The diagnostic value of serum Hsa_circ_ 0007142， SCCA and CYFRA 21-1 levels for NSCLC with stage Ⅰ~ⅡA was analyzed with receiver operating characteristic(ROC) curve. ［Results］ The serum Hsa_circ_0007142 (4.36±1.50 vs 1.08±0.36， 0.90±0.27)， SCCA ［(4.83±1.62) ng/mL vs (0.92±0.31) ng/mL， (0.75±0.14) ng/mL］ and CYFRA21-1 ［(6.84±2.10) ng/mL vs (2.50±0.58) ng/mL，(1.81±0.35) ng/mL］ levels in NSCLC group were significantly higher than those in benign group and control group (P all<0.001). The levels of serum Hsa_circ_0007142 (5.75±1.96 vs 3.10±1.05) and SCCA［ (6.05±2.04) ng/mL vs (3.64±1.21) ng/mL) and CYFRA21-1 ［(8.70±2.73) ng/mL vs (5.06±1.70) ng/mL］ in NSCLC of ⅡB~Ⅳ stage were significantly higher than those of Ⅰ~ⅡA stage (P all<0.001). The serum Hsa_circ_0007142 levels were significantly increased in NSCLC patients with poorly differentiation， lymph node metastasis， distant metastasis， positive SCCA and positive CYFRA21-1 (P all<0.05). ROC curve analysis showed that Hsa_circ_0007142≥2.85 had the highest specificity (87.4%) for diagnosing stage Ⅰ~ⅡA NSCLC， and the area under the curve(AUC) of Hsa_circ_0007142 combined with SCCA and CYFRA21-1 for diagnosing stage Ⅰ~ⅡA NSCLC was the largest (AUC =0.938， 95%CI： 0.877~0.995) with the highest sensitivity (97.5%).［Conclusion］ The serum Hsa_circ_0007142 level is significantly increased in patients with NSCLC ， which is related to the progression of clinical and pathological features. The combined detection of Hsa_circ_0007142， SCCA and CYFRA21-1 has certain value for diagnosis of Ⅰ~ⅡA stage NSCLC. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |